Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED95 of remifentanil with remimazolam for tracheal intubation in elderly patients
ChiCTR2500095646Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remifentanil and remimazolam in perioperative care, sponsored by Qilu Hospital of Shandong University. Primary endpoint: ED50 and ED95 for suppression of tracheal intubation response. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
remifentanilremimazolam
03
Conditions
perioperative care
Beyond the preview
Go deeper on ChiCTR2500095646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095646.